Universiti Malaya Medical Centre

Dr. Universiti Malaya Medical Centre

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
OHOndrej Hrusak
Ondrej Hrusak
TKTomas Kalina
Tomas Kalina
JWJoshua Wolf
Joshua Wolf
ABAdriana Balduzzi
Adriana Balduzzi
MPMassimo Provenzi
Massimo Provenzi
MSMartin Schrappe
Martin Schrappe

20 March 2017 in Microbiome
Verified
Journal Article
Open access
PDF file
LCLing Ling Chua
Ling Ling Chua
RRReena Rajasuriar
Reena Rajasuriar
MAMohamad Shafiq Azanan
Mohamad Shafiq Azanan
NANoor Kamila Abdullah
Noor Kamila Abdullah
MTMei San Tang
Mei San Tang
PLP’ng Loke
P’ng Loke
Adult survivors of childhood cancers such as acute lymphoblastic leukemia (ALL) have health problems that persist or develop years after cessation of therapy. These late effects include chronic inflammation-related comorbidities such as obesity and type 2 diabetes, but the underlying cause is poorly understood. We compared the anal microbiota composition of adult survivors of childhood ALL (N = 73) with healthy control subjects (N = 61). We identified an altered community with reduced microbial diversity in cancer survivors, who also exhibit signs of immune dysregulation including increased T cell activation and chronic inflammation. The bacterial community among cancer survivors was enriched for Actinobacteria (e.g. genus Corynebacterium) and depleted of Faecalibacterium, correlating with plasma concentrations of IL-6 and CRP and HLA-DR+CD4+ and HLA-DR+CD8+ T cells, which are established markers of inflammation and immune activation. We demonstrated a relationship between microbial dysbiosis and immune dysregulation in adult ALL survivors. These observations suggest that interventions that could restore microbial diversity may ameliorate chronic inflammation and, consequently, development of late effects of childhood cancer survivors.

27 June 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
UCUniversiti Malaya Medical Centre
Universiti Malaya Medical Centre
MAMohamad Shafiq Azanan
Mohamad Shafiq Azanan
SGSayyidatul Syahirah Abd Ghafar
Sayyidatul Syahirah Abd Ghafar
LOLixian Oh
Lixian Oh
KLKee Hie Lau
Kee Hie Lau
PHPierre Hainaut
Pierre Hainaut

24 February 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LCLing Ling Chua
Ling Ling Chua
RRReena Rajasuriar
Reena Rajasuriar
YLYvonne Ai Lian Lim
Yvonne Ai Lian Lim
YWYin Ling Woo
Yin Ling Woo
PLP’ng Loke
P’ng Loke
UCUniversiti Malaya Medical Centre
Universiti Malaya Medical Centre
Background: Alteration in gut microbiota has been recently linked with childhood leukemia and the use of chemotherapy. Whether the perturbed microbiota community is restored after disease remission and cessation of cancer treatment has not been evaluated. This study examines the chronological changes of gut microbiota in children with acute lymphoblastic leukemia (ALL) prior to the start-, during-, and following cessation of chemotherapy.Methodology: We conducted a longitudinal observational study in gut microbiota profile in a group of paediatric patients diagnosed with ALL using 16 s ribosomal RNA sequencing and compared these patients’ microbiota pattern with age and ethnicity-matched healthy children. Temporal changes of gut microbiota in these patients with ALL were also examined at different time-points in relation to chemotherapy.Results: Prior to commencement of chemotherapy, gut microbiota in children with ALL had larger inter-individual variability compared to healthy controls and was enriched with bacteria belonging toBacteroidetesphylum andBacteroidesgenus.The relative abundance ofBacteroidesdecreased upon commencement of chemotherapy. Restitution of gut microbiota composition to resemble that of healthy controls occurred after cessation of chemotherapy. However, the microbiota composition (beta diversity) remained distinctive and a few bacteria were different in abundance among the patients with ALL compared to controls despite completion of chemotherapy and presumed restoration of normal health.Conclusion: Our findings in this pilot study is the first to suggest that gut microbiota profile in children with ALL remains marginally different from healthy controls even after cessation of chemotherapy. These persistent microbiota changes may have a role in the long-term wellbeing in childhood cancer survivors but the impact of these changes in subsequent health perturbations in these survivors remain unexplored.

16 April 2012 in Breast Cancer Research
Verified
Journal Article
Open access
DLDaphne Sc Lee
Daphne Sc Lee
SYSook-Yee Yoon
Sook-Yee Yoon
Lai Meng LooiLai Meng Looi
Lai Meng Looi
PKPeter Kang
Peter Kang
IKIn Nee Kang
In Nee Kang
STSoo-Hwang Teo
Soo-Hwang Teo
Introduction: Germline TP53 mutations cause an increased risk to early-onset breast cancer in Li-Fraumeni syndrome (LFS) families and the majority of carriers identified through breast cancer cohorts have LFS or Li-Fraumeni-like (LFL) features. However, in Asia and in many low resource settings, it is challenging to obtain accurate family history and we, therefore, sought to determine whether the presence of early-onset breast cancer is an appropriate selection criteria for germline TP53 testing. Methods: A total of 100 patients with early-onset breast cancer (≤ 35 years) treated at University Malaya Medical Centre between 2003 and 2009, were analyzed for germline mutations in BRCA1, BRCA2 and TP53 by full DNA sequencing. Of the mutations identified, we examined their likely pathogenicity on the basis of prevalence in a case-control cohort, co-segregation analyses and loss of heterozygosity (LOH) in tumor tissues. Results: We identified 11 BRCA1 (11%) and 6 BRCA2 (6%) germline carriers among early-onset breast cancer patients. Of the 83 BRCA-negative patients, we identified four exonic variants and three intronic variants in TP53. Of these, two exonic variants are clinically relevant (E346X and p. G334_R335dup6) and two novel missense mutations (A138V and E285K) are likely to be clinically relevant, on the basis of co-segregation and loss of heterozygosity (LOH). Notably, E285K was found in two unrelated individuals and haplotype analyses suggest a founder effect. Two of the three intronic variants are likely benign based on their prevalence in a control population. Clinically relevant TP53 germline mutations were identified in three of the four patients (75%) with a family history of at least two LFS-linked cancers (breast, bone or soft tissue sarcoma, brain tumors or adrenocortical cancer); 1 of the 17 patients (6%) with a family history of breast cancer only, and 1 of the 62 patients (< 2%) with no family history of breast or LFS-linked cancers. Conclusions: Our study reports germline BRCA1, BRCA2 and TP53 mutations are found in early-onset breast cancer patients at 11%, 6% and 5% respectively, suggesting that TP53 mutation screening should be considered for these patients. However, we find that even in low resource Asian settings where family history is poorly reported, germline TP53 mutations are found predominantly among breast cancer patients with a family history of LFS-linked cancers.

31 March 2010 in Leukemia Research
Verified
Journal Article
Closed access
AYAllen EJ Yeoh
Allen EJ Yeoh
YLYi Lu
Yi Lu
JCJason Yong-Sheng Chan
Jason Yong-Sheng Chan
YCYiong Huak Chan
Yiong Huak Chan
UCUniversiti Malaya Medical Centre
Universiti Malaya Medical Centre
TQThuan Chong Quah
Thuan Chong Quah